GlassScriptPhysician profile
Kaylee Ann Nelson
NPI 1770004319
$3,993.40
in general payments reported to CMS, 2019-2025
31 companies · $555 in 2025
The $555 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,286 · 2022: $1,276 · 2023: $489 · 2024: $388 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,431.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,133.87 | 2021-2025 | Proclaim, Eterna |
| Medtronic, INC. | $508.01 | 2021-2025 | Intellis Adaptivestim |
| Nevro Corp. | $457.44 | 2021-2024 | Senza |
| Abbvie INC. | $312.70 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $216.54 | 2021-2022 | |
| Pfizer INC. | $211.54 | 2021-2025 | |
| Scilex Pharmaceuticals INC. | $149.17 | 2021-2024 | Ztlido |
| Stimwave Technologies Incorporated | $123.03 | 2021 | |
| Biodelivery Sciences International, INC. | $121.18 | 2021 | |
| Supernus Pharmaceuticals, INC. | $93.13 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $76.01 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $63.35 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $55.83 | 2022 | |
| Allergan, INC. | $54.01 | 2021 | |
| Grt US Holding, INC. | $53.72 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $42.11 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $33.44 | 2025 | |
| Alnylam Pharmaceuticals INC. | $33.40 | 2021 | |
| Horizon Therapeutics Plc | $32.89 | 2021 | |
| Argenx US, INC. | $28.54 | 2025 | Vyvgart Hytrulo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.88 | 2025 | Jardiance |
| Tonix Medicines, INC. | $24.00 | 2025 | Tonmya |
| Tersera Therapeutics LLC | $22.74 | 2021 | |
| Redhill Biopharma INC. | $18.00 | 2021 | |
| Nalu Medical, INC. | $17.88 | 2021 | |
| Eisai INC. | $15.99 | 2021 | |
| Lilly USA, LLC | $15.00 | 2021 | |
| Ibsa Pharma INC. | $14.40 | 2021 | |
| Relievant Medsystems, INC. | $13.83 | 2022 | |
| Forte Bio-Pharma LLC | $12.19 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaylee Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.